EBA Supports Clinical Trials in the Ukraine
The European Business Association came out in support of clinical trials in Ukraine.
The European Business Association (EBA) came out in support of the Ukraine by outlining the positives of the country's clinical trials and research industry. The EBA acknowledged the political and military issues in the country, and agreed that the areas of Donetsk, Luhansk and Crimea are the exception to an otherwise normal situation for conducting clinical trials.According to its information, the Ukraine is currently only at 10%-15% of its potential for conducting trials.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
